Last reviewed · How we verify
Neoadjuvant Olaparib monotherapy group — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Neoadjuvant Olaparib monotherapy group (Neoadjuvant Olaparib monotherapy group) — AstraZeneca.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Neoadjuvant Olaparib monotherapy group TARGET | Neoadjuvant Olaparib monotherapy group | AstraZeneca | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Neoadjuvant Olaparib monotherapy group CI watch — RSS
- Neoadjuvant Olaparib monotherapy group CI watch — Atom
- Neoadjuvant Olaparib monotherapy group CI watch — JSON
- Neoadjuvant Olaparib monotherapy group alone — RSS
Cite this brief
Drug Landscape (2026). Neoadjuvant Olaparib monotherapy group — Competitive Intelligence Brief. https://druglandscape.com/ci/neoadjuvant-olaparib-monotherapy-group. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab